The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is: • Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation? Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation. Persons with atrial fibrillation who are planned for an electric cardioversion will: * Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days * Undergo a planned electric cardioversion of the atrial fibrillation * Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
1,600
Tablet Dapagliflozin 10 mg orally during from randomization for maximum 56 days.
Linköping university hosptial
Linköping, Sweden
NOT_YET_RECRUITINGÖrebro University hospital
Örebro, Sweden
RECRUITINGSödersjukhuset
Stockholm, Sweden
NOT_YET_RECRUITINGKarolinska University Hospital
Stockholm, Sweden
RECRUITINGDanderyds Hospital
Stockholm, Sweden
NOT_YET_RECRUITINGNorrlands universitetssjukhus
Umeå, Sweden
NOT_YET_RECRUITINGAkademiska sjukhuset
Uppsala, Sweden
NOT_YET_RECRUITINGAtrial fibrillation recurrence
Time to first AF recurrence detected with an ECG- monitoring device within 30 days after planned elective electrical cardioversion.
Time frame: 30 days after elective electrical cardioversion
Proportion of patients in SR at 30 days
Proportion of patients in SR 30 days after cardioversion.
Time frame: 30 days after elective electrical cardioversion
Proportion of patients without any atrial fibrillation recurrence at 30 days
Proportion of patients without any atrial fibrillation recurrence at 30 days
Time frame: 30 days after elective electrical cardioversion
Time to spontaneous return to sinus rhythm before electrical cardioversion
Time to spontaneous return to sinus rhythm measured from randomization to electrical cardioversion (max 26 days)
Time frame: Up to 26 days
Spontaneous return to sinus rhythm before cardioversion.
Number of patients with return to sinus rhythm at time of electrical cardioversion (maximum 26 days from randomization)
Time frame: Up to 26 days
Success of cardioversion
Discharged with sinus rhythm after electric cardioversion
Time frame: Periprocedural
Total number of days with atrial fibrillation
Total number of days with AF recordings during the 30 days following cardioversion.
Time frame: From day of electric cardioversion to 30 days after
Absence of clinical atrial fibrillation recording
Absence of clinical atrial fibrillation recurrence (12-lead ECG-verified) during follow-up after cardioversion or after spontaneous return to SR (before cardioversion).
Time frame: From randomization to 30 days after electric cardioversion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.